Global bioproduction company 21st.BIO today announced it is granting access to its precision fermentation technology platform to ingredient manufacturers.
This follows 21st.BIO’s successful scaling of the beta-lactoglobulin protein, a major protein in milk that provides highly valuable nutrition and textural components of milk and other dairy ingredients.
By offering its precision fermentation technology platform widely, 21st.BIO mitigates the cost and time associated with development, opening access to proven industrial scale production technology for precision fermentation of alternative proteins.
The platform provides a sustainable and less carbon and resource intensive alternative to traditional animal-based production methods, helping to stabilise global food supply chains.
According to recent studies, producing proteins via precision fermentation reduces greenhouse gases (GHG) emissions, and land and water use by 90 to 96%, compared to animal-derived production.
With 21st.BIO’s platform, customers have access to world-leading industrial production strains, fermentation processes, as well as support with scale-up, tech transfers to contract manufacturers and regulatory approvals to get to market at speed and with lower costs.
21st.BIO continuously endeavours to optimise the strains and processes, ensuring customers are always ahead of the market.
The technology foundation is licensed from Novozymes, who has 40 years’ experience perfecting production strains and processes for industrial production. The technology base is already used to provide dozens of food-grade products on the market today.
21st.BIO’s technology can be optimised for each customer’s specific purpose, such as the nutritional fortification of a plant-based product, improvement of texture in alternative dairy and medical nutrition.
Customers of 21st.BIO can be innovative start-ups planning to take one or several proteins to the market, or established players expanding into sustainable alternatives and dairy companies aiming to grow with the increasing global demand for proteins while reducing their footprint on the environment.
Thomas Schmidt, CEO of 21st.BIO said: “We founded 21st.BIO with one simple mission: to make precision fermentation technology accessible to as many companies as possible, so they can successfully take their product to market at a competitive price. We believe this is the best way for technology to support and accelerate the transition to more sustainable and better nutrition globally. With this new offering, I am proud that companies will be able to safely scale innovation into industrial production and meet global demand utilising our technology and expertise.”
